Size, Share & Industry Analysis, By Technology (Next-Generation Sequencing, PCR and Digital PCR, Flow Cytometry, IHC and ISH, Cytogenetics), By Cancer Indication (Leukemia, Lymphoma, Multiple Myeloma, Other Hematologic Malignancies), By End User (Clinical Laboratories, Hospitals, Academic and Research Institutions), By Testing Purpose (Initial Diagnosis and Classification, Prognosis and Therapy Selection, Residual Disease and Response Monitoring), and Regional Forecast, 2026-2034
Explore the report section by section.
The global Hematology Oncology Diagnostics Market reached USD 2.9 billion in 2025, with a USD 3.1 billion estimate for 2026 and a projected USD 5.5 billion by 2034. The forecast represents a 7.4% CAGR during 2026–2034, as leukemia, lymphoma and myeloma testing increasingly combines morphology, immunophenotyping and molecular evidence to support treatment selection.
The International Agency for Research on Cancer reported 20.6 million new cancer diagnoses worldwide for 2024 across 34 cancers, establishing the scale of oncology testing demand. Blood cancers require more than a positive screening result: laboratory teams classify cellular lineage, detect driver alterations, distinguish reactive from malignant changes and monitor molecular response. A complete diagnostic pathway may combine bone marrow morphology with flow cytometry, cytogenetic analysis and DNA or RNA sequencing. Each modality answers a different clinical question, which sustains reagent and interpretation demand even when a new assay replaces part of an older workflow.
Clinical use of measurable residual disease testing is widening in lymphoid malignancies. In January 2026, the U.S. FDA released draft guidance discussing flow cytometry- and sequencing-based MRD negativity in multiple myeloma trials. Adaptive Biotechnologies reported a September 2026 update to myeloma practice recommendations that included sensitive MRD assessment. Medicare coverage for selected clonoSEQ testing applications also makes repeat testing economically feasible for eligible U.S. patients. These policies do not establish that every MRD assay or disease indication has regulatory clearance; clinical use depends on assay labeling and local laboratory rules.
Technology suppliers are expanding hematologic cancer-specific menus rather than relying on generic tumor panels. QIAGEN and Incyte announced a June 2025 collaboration around a CALR-focused companion diagnostic for myeloproliferative neoplasms, while Pillar Biosciences launched an 80-gene research-use myeloid panel in October 2026. Amoy Diagnostics offers an OncoHeme panel addressing 59 genes in blood or marrow samples. Roche supplies hematopathology immunohistochemistry reagents, and Bio-Rad provides a cleared BCR-ABL digital-PCR monitoring workflow. These products address distinct stages of the testing pathway and should not be described as interchangeable.
North America represented an estimated ~42% of global hematology oncology diagnostics revenue in 2025, reflecting broad molecular laboratory capacity and reimbursement for selected residual-disease tests. Europe benefits from public genomic testing networks but must comply with the EU in-vitro diagnostic regulation. Asia-Pacific demand is influenced by Japan’s companion-diagnostic framework, China’s domestic assay suppliers and Australia’s precision-medicine investment. Latin America and Africa face greater laboratory access constraints; international cancer-survival programs document the importance of timely diagnosis, trained personnel and specimen transport.
Source: IARC 2024 global cancer estimates; FDA MRD draft guidance; QIAGEN–Incyte collaboration.
Hematology oncology diagnostic revenue includes assays, dedicated instruments, consumables and attributable laboratory testing for malignant blood and lymphoid disorders. Molecular and cellular methods are counted once at the billed diagnostic service or product level.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million/billion |
| By Technology | Next-Generation Sequencing; PCR and Digital PCR; Flow Cytometry; IHC and ISH; Cytogenetics |
| By Cancer Indication | Leukemia; Lymphoma; Multiple Myeloma; Other Hematologic Malignancies |
| By End User | Clinical Laboratories; Hospitals; Academic and Research Institutions |
| By Testing Purpose | Initial Diagnosis and Classification; Prognosis and Therapy Selection; Residual Disease and Response Monitoring |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; United Kingdom; Germany; Japan; China; Australia; India; Brazil; Mexico; South Africa; Kenya |
| Key Market Players | Roche Diagnostics; QIAGEN N.V.; Thermo Fisher Scientific; Illumina, Inc.; Bio-Rad Laboratories; Adaptive Biotechnologies; Invivoscribe, Inc.; Amoy Diagnostics Co., Ltd.; Foresight Diagnostics; Pillar Biosciences |
The market includes hematologic-malignancy-attributable diagnostic kits, reagents, instruments, sequencing consumables, flow-cytometry panels, hematopathology staining products and contracted clinical testing services. Revenue is assigned to leukemia, lymphoma, myeloma or other blood cancers according to the primary intended diagnostic indication. General oncology testing for solid tumors, routine nonmalignant blood counts, imaging-only oncology procedures and unrelated research platforms are outside this boundary.
Clinical laboratory fees are counted when they represent the diagnostic service sold to a healthcare customer; the same assay kit is not added again as a separate final-market sale in a combined revenue calculation. Research-use-only products from Thermo Fisher or Pillar are distinguished from approved in-vitro diagnostics, and investigational companion tests are not described as authorized for routine clinical decision-making.
Drivers Impact Analysis*
| Market Drivers | Impact Rank | CAGR Contribution (%) | 2026–2028 | 2029–2031 | 2032–2034 |
|---|---|---|---|---|---|
| Expanded MRD testing in myeloma and lymphoid malignancies | High | +3.10% | High | High | High |
| Mutation-guided leukemia and lymphoma treatment selection | Medium-High | +2.20% | High | High | Medium |
| Automation of hematologic sequencing and sample preparation | Medium | +1.70% | Medium | High | High |
| Public genomic laboratory network investment | Low-Medium | +1.10% | Medium | Medium | High |
| Others (clinical trials, assay menu expansion, pathology training) | Low | +0.90% | Medium | Medium | Medium |
Restraints Impact Analysis*
| Market Restraints | Impact Rank | CAGR Contribution (%) | 2026–2028 | 2029–2031 | 2032–2034 |
|---|---|---|---|---|---|
| NGS capital and bioinformatics operating costs | High | -0.85% | High | Medium | Medium |
| IVDR validation and payer evidence requirements | Medium-High | -0.50% | High | Medium | Medium |
| Others (specimen logistics, workforce scarcity, reimbursement gaps) | Medium | -0.25% | High | Medium | Low |
*CAGR contribution shows the percentage points each factor adds to or removes from the 7.4% CAGR for 2026–2034; driver contributions less restraint contributions equal the market CAGR. Period columns rate the strength of each factor in that window.
The WHO and IARC cancer-survival programs describe major variation in access to timely diagnosis, while hematologic malignancies demand specialized classification. A suspected leukemia case may require marrow morphology, immunophenotyping and a fusion-gene assay before clinicians can choose a regimen. Repeated testing can follow treatment because malignant clones may persist beneath the detection threshold of conventional microscopy. Hospitals that establish standardized referral arrangements for marrow and blood specimens can increase test completion, but complex transport and pathology staffing remain constraints in underserved areas.
The FDA published January 2026 draft guidance on MRD negativity and complete response in multiple myeloma, explicitly discussing sequencing and flow-cytometry approaches. Adaptive Biotechnologies subsequently described September 2026 updates to myeloma testing recommendations. Such developments can increase longitudinal assay volume because treatment response may be evaluated at multiple clinical milestones. Reimbursement, however, remains indication-specific: a test accepted for one lymphoid disease or specimen cannot automatically be billed or used under another authorization. This creates separate commercial adoption curves for multiple myeloma, chronic lymphocytic leukemia and lymphoma.
QIAGEN and Incyte disclosed a June 2025 partnership to develop a multimodal panel focused initially on mutant CALR in myeloproliferative neoplasms. The collaboration illustrates how targeted investigational medicines require assays able to identify eligible molecular subgroups. Invivoscribe registered its FLT3 companion diagnostic in the United Kingdom and Switzerland in March 2025, supporting mutation-informed acute myeloid leukemia decisions. Companion tests must match the intended therapeutic indication, and validation costs may delay access outside specialized reference laboratories.
NGS instruments, quality-control materials, informatics and trained molecular pathologists raise the fixed cost of hematology oncology diagnostics. NHS England coordinates seven genomic laboratory hubs to concentrate expertise, but countries without comparable networks may send marrow specimens over long distances. Automation reduces manual library preparation, yet the interpretation of complex fusions and low-frequency variants still requires laboratory governance. Cost-sensitive systems therefore prioritize targeted PCR or immunophenotyping before introducing larger sequencing panels, creating uneven demand across hospital tiers.
Noridian documented a January 2025 MolDX coding revision for hematologic MRD testing, including a mantle-cell lymphoma use case for clonoSEQ. In Europe, the Commission updated IVD classification guidance in March 2025, affecting manufacturers that market diagnostic devices under IVDR. Japan’s PMDA published companion-diagnostic approval lists updated during 2026. These separate frameworks determine which laboratories can offer tests, what evidence must be submitted and whether repeat monitoring can be reimbursed, influencing realized revenue rather than merely clinical interest.
Sources: FDA January 2026 MRD guidance; Noridian April 2025 MolDX notice; European Commission IVDR classification guidance; PMDA 2026 companion diagnostic lists.
Pillar Biosciences expanded its myeloid research panel to 80 genes in October 2026, with additional FLT3-ITD detection capability. Amoy Diagnostics describes a 59-gene OncoHeme assay for variants and fusions in blood or marrow. Thermo Fisher offers research-use myeloid panels that detect mutations at low variant frequencies, while Illumina introduced the fireflyGO preparation platform in May 2026. These examples show laboratory demand for faster specimen-to-variant workflows, although clinical authorization remains distinct from research availability. Laboratories implementing Illumina workflows also need validated quality-control and informatics procedures for patient specimens.
Foresight Diagnostics presented prospective multicenter CLARITY results in May 2025 for diffuse large B-cell lymphoma, reporting residual-disease findings from more than 150 patients across Dutch and Belgian sites. Its subsequent QIAGEN partnership proposed a kit-based assay for future diagnostic and companion uses. Adaptive Biotechnologies also enhanced clonoSEQ sensitivity for DLBCL in March 2025. Blood-based monitoring may reduce dependence on repeated invasive procedures in selected pathways, but each assay requires clinical validation before replacing established pathology tests.
Adaptive Biotechnologies and Flatiron Health integrated clonoSEQ ordering and results into OncoEMR in July 2025, providing access across a network of more than 4,500 clinicians. Digital ordering can improve sample tracking, support repeat-testing schedules and reduce manual report transfer. Laboratories must still maintain correct patient identifiers, specimen handling controls and interpretive review. Health systems using interoperable oncology records are positioned to make molecular monitoring easier for community physicians without moving every patient to a tertiary cancer center.
Roche supplies more than 60 hematopathology IHC and ISH reagents for lymphoma, leukemia and myeloma, supporting tissue-based classification. Bio-Rad markets a cleared BCR-ABL digital-PCR workflow for chronic myeloid leukemia monitoring. In contrast, Pillar oncoReveal Lymphoid and Thermo Fisher Oncomine Myeloid MRD are identified as research-use products in their published materials. Purchasing decisions increasingly depend on the exact clinical claim, laboratory accreditation, specimen type and reimbursement pathway rather than the number of genes printed on a panel.
NHS England’s national test directory identifies eligible genomic investigations and connects them with seven genomic laboratory hubs. Australia committed A$143.4 million in March 2025 to extend pediatric and adult cancer precision programs, while Japan updates its companion-diagnostic approvals centrally. Brazil’s INCA molecular laboratory documents NGS applications in hematologic neoplasms, yet PAHO continues to report delays in childhood cancer diagnosis elsewhere in the Americas. Networked reference laboratories can spread instrument costs across higher specimen volumes.
Technology segmentation separates Next-Generation Sequencing, PCR and Digital PCR, Flow Cytometry, IHC and ISH, and Cytogenetics. Each diagnostic transaction is assigned to its primary billed modality, so an integrated case review does not allocate the same service fee to several platforms. Assay choice reflects the question being asked and the specimen available.
Next-Generation Sequencing represented an estimated ~35% of 2025 revenue. Panels for AML, MPN and lymphoid cancers interrogate driver mutations and rearrangements at once. AmoyDx OncoHeme covers 59 genes, while Pillar launched an 80-gene myeloid research panel in October 2026. Sequencing offers high information density, although instrument expense and interpretation limit adoption in smaller laboratories.
PCR and Digital PCR remain important for rapid mutation calls and quantification of known disease markers. Bio-Rad’s cleared QXDx BCR-ABL workflow addresses chronic myeloid leukemia monitoring, while Invivoscribe’s FLT3 assay supports an acute leukemia companion-diagnostic pathway. Targeted methods often have shorter analytic workflows than broad panels when clinicians already know the relevant biomarker.
Flow Cytometry classifies abnormal blood and marrow cell populations through immunophenotypic marker combinations. The FDA’s January 2026 myeloma draft guidance recognizes flow-based MRD measurement alongside sequencing. Standardization and experienced gating are essential because low-frequency malignant populations can resemble regenerating normal cells after therapy.
Roche’s hematopathology portfolio provides ready-to-use IHC and ISH reagents for lymphoma and leukemia classification. Cytogenetics remains necessary for detecting chromosomal architecture and clinically important rearrangements not fully resolved by a narrow mutation assay. Laboratories combine these methods with molecular panels rather than treating one technology as a universal replacement.
Future modality allocation will depend on reimbursement for serial MRD, hospital sequencing capacity and the migration of specialist assays into accredited clinical workflows. Pillar’s October 2026 research-only launch does not constitute FDA authorization for routine diagnostic use.
Cancer-indication allocation assigns each test to Leukemia, Lymphoma, Multiple Myeloma or Other Hematologic Malignancies. Disease categories are mutually exclusive at the primary clinical indication level even when a platform can test several malignancies. Different relapse patterns and therapeutic biomarkers create distinct testing schedules.
Leukemia represented an estimated ~42% of 2025 revenue. Acute myeloid leukemia frequently requires FLT3, IDH, NPM1 and other mutation assessment, and chronic myeloid leukemia relies on quantitative BCR-ABL monitoring. Invivoscribe expanded FLT3 test registration in March 2025, while Brazil incorporated an MRD-relevant adult ALL therapy in August 2025. The 2025 Brazilian ALL policy also increases attention to measurable residual disease during post-treatment surveillance.
Lymphoma testing spans tissue immunohistochemistry, immunophenotyping and increasingly circulating tumor DNA studies. Foresight’s 2025 multicenter CLARITY data addressed diffuse large B-cell lymphoma, and Pillar’s 84-gene Lymphoid research panel launched in November 2025. Adoption depends on whether molecular findings alter therapy or monitoring decisions for the particular lymphoma subtype.
Multiple Myeloma creates repeated testing opportunities as response criteria incorporate sensitive residual-disease assessments. FDA draft guidance in January 2026 discussed MRD negativity as a potential trial endpoint, and Adaptive described guideline updates in September 2026. Marrow sampling remains clinically important, and coverage for repeat tests varies by patient pathway.
Other Hematologic Malignancies includes myelodysplastic syndromes and myeloproliferative neoplasms not already counted under leukemia. QIAGEN and Incyte’s CALR collaboration focuses on mutant-calreticulin MPN populations. Smaller patient pools may require specialized assay menus and referral to reference laboratories rather than local high-volume platforms.
Leukemia diagnostic spending differs by disease stage, molecular risk and the intensity of subsequent treatment. Mutation-guided prescribing and follow-up MRD testing can increase assays per patient without a comparable increase in new cancer diagnoses.
End users comprise Clinical Laboratories, Hospitals, and Academic and Research Institutions. The classification is based on the entity purchasing the assay or receiving the contracted diagnostic service, not on where a patient was first examined. Referral relationships move samples without creating a second market transaction.
Clinical Laboratories account for the largest share of revenue because reference networks concentrate NGS platforms, quality controls and specialist interpretation. NHS England operates seven genomic laboratory hubs to coordinate national testing, illustrating how centralized commissioning can raise utilization. Independent laboratories also offer billed MRD testing when an assay meets clinical and payer requirements.
Hospitals retain extensive pathology, flow-cytometry and molecular services for urgent leukemia classification. A hospital with an accredited hematopathology department can complete time-sensitive marrow workups internally while referring rare molecular tests to outside specialists. Clinical demand rises when therapeutic decisions require immediate mutation or lineage information.
Academic and Research Institutions use research-only panels to study novel mutations, refine MRD thresholds and validate future companion tests. Foresight’s Netherlands-Belgium multicenter lymphoma studies and the ELN AML MRD consensus work demonstrate the research pipeline supporting future clinical protocols. Such revenue is counted only when the product or service is sold for an in-scope hematologic malignancy application.
Laboratory consolidation can shift instrument purchases toward fewer high-throughput centers, while hospitals continue to generate specimen demand and provide clinical interpretation.
Testing purpose separates Initial Diagnosis and Classification, Prognosis and Therapy Selection, and Residual Disease and Response Monitoring. A single assay is assigned according to the documented clinical intent for that test order. A new MRD test order is a separate transaction only when the clinician documents a distinct monitoring need.
Initial Diagnosis and Classification is the leading use case, encompassing confirmation of malignant cell lineage and genomic subtype. Roche IHC and ISH panels support tissue classification, and targeted NGS can identify fusions in AML. Rapid diagnosis is particularly important in acute leukemias because treatment pathways depend on both clinical urgency and molecular risk.
Prognosis and Therapy Selection includes mutation testing linked to targeted drugs and clinical risk stratification. QIAGEN’s CALR partnership and Invivoscribe’s FLT3 companion assay illustrate biomarker-specific development. Clinicians require evidence that an assay predicts or guides a treatment decision, not simply that it detects a genomic variant.
Residual Disease and Response Monitoring encompasses serial sequencing, flow cytometry and quantitative PCR after therapy. Adaptive’s clonoSEQ integration into oncology records in July 2025 addresses repeated ordering and result review. The FDA myeloma draft guidance and Medicare coverage changes support growth, but not all disease-specific uses share the same authorization.
As hematologic therapy becomes more individualized, serial monitoring may expand faster than initial testing, provided coverage and laboratory capacity support repeat assessment.
Regional purchasing reflects the distribution of specialized hematopathology laboratories, reimbursement for molecular monitoring and public investment in genomic medicine. The geographic model totals 100% of 2025 revenue across five nonoverlapping regions.
North America represented an estimated ~42% of 2025 global hematology oncology diagnostics revenue. The United States supports a broad network of molecular reference laboratories, hematopathology centers and oncology clinics that order sequential testing. Medicare MolDX policies cover selected MRD indications, including mantle-cell lymphoma surveillance under documented criteria, while private coverage can vary by disease and specimen. Adaptive Biotechnologies integrated clonoSEQ into Flatiron OncoEMR in July 2025, reaching a network of more than 4,500 clinicians and reducing the steps required for test ordering. Clinical laboratories can therefore receive more follow-up samples without expanding every hospital’s sequencing footprint. Canada participates through provincial cancer programs and specialist laboratory referrals, although funding decisions are not identical to U.S. coverage rules. FDA draft myeloma guidance issued in January 2026 could influence future trial designs, but it is not a blanket authorization of all MRD tests. Higher assay prices and repeat monitoring intensity support regional revenue leadership.
Noridian published a 2025 MolDX coding update that added a clonoSEQ use case for patients with a history of mantle-cell lymphoma. Adaptive’s July 2025 OncoEMR integration connected test ordering and results to more than 4,500 clinicians. These developments support recurring molecular monitoring in eligible blood-cancer patients, although local medical-necessity rules and test indications remain decisive for payment.
Source: Noridian Medicare.
European laboratories use national cancer pathways and specialist reference centers for leukemia and lymphoma molecular characterization. NHS England coordinates seven genomic laboratory hubs, and its National Genomic Test Directory specifies eligible investigations for publicly commissioned care. The network reduces duplication of expensive equipment while connecting local hospitals with accredited interpretation teams. In March 2025 the European Commission updated classification guidance for in-vitro diagnostic devices under IVDR, adding regulatory work for manufacturers seeking European clinical access. Research laboratories remain active in evaluating ctDNA and molecular residual disease, with Foresight’s Dutch-Belgian lymphoma study spanning more than 150 patients and 50 sites in 2025. Commercial uptake is moderated by national reimbursement decisions and differences between research-use assays and CE-marked diagnostics. Germany, France and the United Kingdom host large hematopathology services, while smaller countries may rely on cross-border or centralized referral arrangements. Investment in workflow automation can help laboratories handle broader panels without matching increases in specialist staffing.
Invivoscribe reported UK registration of its LeukoStrat FLT3 companion assay in March 2025. NHS England’s genomic test directory defines who qualifies for commissioned molecular investigations, and seven laboratory hubs coordinate regional service delivery. These arrangements allow clinicians to request specialist leukemia assays while central laboratories maintain validation, specimen quality and interpretation controls.
Source: Invivoscribe.
Asia-Pacific combines high-volume cancer systems with rapidly developing domestic sequencing and diagnostic manufacturing. Amoy Diagnostics markets an OncoHeme NGS panel targeting 59 genes associated with hematologic malignancies, providing an example of regionally developed assays. Japan maintains published companion-diagnostic approval lists through PMDA, including updates during 2026, and clinical laboratories must distinguish approved indications from exploratory genomic tests. Australia’s government announced A$143.4 million in March 2025 to extend pediatric and adult cancer precision programs, supporting complex genomic workflows and data interpretation. India’s private laboratory networks are adding molecular testing capacity, although cost and referral logistics can limit availability outside major urban centers. Clinical uptake differs between markets because reimbursement, laboratory accreditation and the local availability of trained molecular pathologists vary. Higher cancer caseloads alone do not establish equivalent diagnostic spending; test mix and price remain important. Reference centers are likely to expand first where sample volumes support equipment utilization.
PMDA published companion-diagnostic lists updated in September 2026 for identifying treatment-eligible patients and August 2026 for drug-agnostic use. Japanese laboratories can use these lists to confirm authorized claims before adopting mutation-directed hematologic assays. Product reimbursement and clinical utility remain separate decisions, so research sequencing panels cannot automatically substitute for approved tests.
Source: PMDA.
Latin American demand for hematology oncology diagnostics is shaped by unequal access to specialized laboratories and long specimen-referral routes. PAHO launched a childhood cancer observatory in September 2026 using comparable indicators from 24 countries to identify delays and gaps in care. Earlier PAHO guidance highlighted the importance of rapid recognition and referral for acute leukemia and other childhood cancers. Brazil’s National Cancer Institute describes molecular hematology work using next-generation sequencing, supporting advanced diagnostic capability at major public centers. Brazil also expanded treatment options for adult B-cell acute lymphoblastic leukemia with minimal residual disease in 2025, reinforcing the relevance of accurate response assessment. Mexico and Peru have been part of broader registry and diagnostic improvement initiatives, but the availability of NGS and specialized flow cytometry differs sharply by location. Private reference laboratories can consolidate complex testing, whereas public systems face budget, workforce and logistics barriers. Regional growth therefore depends on improving access to actionable assays, not simply importing higher-priced platforms.
INCA describes a molecular biology laboratory focused on hematologic neoplasms and NGS research. Brazil’s Conitec announced in August 2025 that blinatumomab would be offered to eligible adults with B-cell ALL and residual disease, linking therapeutic pathways to sensitive monitoring. Referral infrastructure and clinical protocols will determine whether advanced molecular tests reach patients beyond specialist oncology centers.
Source: INCA Brazil.
Middle East and Africa contains advanced tertiary cancer centers alongside health systems with limited hematopathology capacity. The WHO’s September 2026 childhood leukemia survival dataset documented substantial regional differences linked to timely diagnosis, treatment access and health-system resources. IARC’s 2026 childhood cancer research program began field activities in Kenya, Malawi and Tanzania, examining diagnostic delays and treatment pathways. These findings show why specimen transport, morphology training and basic immunophenotyping remain foundational before broad NGS adoption. Gulf health systems can support higher-cost molecular testing through specialized hospitals, while many sub-Saharan countries must prioritize referral networks and reliable laboratory supplies. Cross-border partnerships and centralized laboratories may raise test completion without requiring sequencing instruments at every hospital. However, reimbursement and trained personnel remain binding constraints on advanced testing volumes. International initiatives focused on childhood cancer also generate opportunities for standardized diagnostic protocols and longitudinal monitoring, although program announcements should not be mistaken for current assay sales.
IARC reported in September 2026 that its CICERO program was undertaking field activities in Kenya, Malawi and Tanzania to study childhood cancer diagnostic delays, care access and outcomes. The program supports evidence on where referrals and pathology services fail patients. It does not itself establish broad commercial availability of leukemia NGS or MRD assays in Kenya.
Source: IARC.
Competition spans instruments, consumables, clinical assays and centralized testing services. Roche sells hematopathology staining reagents used in leukemia and lymphoma classification, while Illumina supplies sequencing instruments and automated preparation partnerships. QIAGEN develops targeted companion diagnostics with pharmaceutical partners, and Thermo Fisher markets myeloid genomic research workflows. Bio-Rad provides BCR-ABL digital PCR monitoring equipment. Adaptive Biotechnologies operates a clinically deployed MRD testing service, whereas Foresight Diagnostics is developing lymphoma ctDNA tests and kit collaborations. These offerings occupy different positions in the diagnostic chain and should not be compared as if each company sells an identical blood-cancer test.
Roche provides more than 60 IHC and ISH reagents for hematologic malignancies, with automated BenchMark workflows supporting tissue-based lymphoma classification.
QIAGEN is developing a CALR companion panel with Incyte, while Invivoscribe registered a FLT3 companion test in the UK and Switzerland in March 2025.
Adaptive clonoSEQ has covered hematologic indications and EMR connectivity; Foresight CLARITY has been evaluated in prospective lymphoma cohorts and kit-development partnerships.
Pillar introduced an 80-gene myeloid RUO panel in October 2026, and AmoyDx OncoHeme targets 59 genes associated with hematologic cancers.
Illumina’s May 2026 fireflyGO partnership with SPT Labtech illustrates competitive pressure to reduce hands-on library preparation and improve repeatability. Thermo Fisher’s Oncomine Myeloid MRD research assays emphasize low-frequency variant detection from blood or marrow; their research-use labeling must be respected in commercial claims. Bio-Rad’s QXDx BCR-ABL workflow occupies a narrower but clinically established monitoring niche. Hospitals choose between local deployment and send-out testing based on case volume, staffing, quality controls and reporting time. A lower instrument purchase price does not necessarily mean a lower cost per clinically interpretable result.
Foresight’s May 2025 multicenter DLBCL study reported 24% MRD positivity at end of treatment and differences in subsequent outcomes, demonstrating demand for longitudinal molecular evidence. Its QIAGEN kit partnership could broaden future access if clinical validation and authorization are achieved. Amoy Diagnostics offers a targeted IDH1/2 PCR panel alongside its broader sequencing products, allowing different laboratories to select a suitable testing depth. Supplier partnerships can combine assay content, instruments and bioinformatics, but regulatory responsibility remains tied to the specific intended use.
Noridian’s 2025 coverage update and FDA’s 2026 guidance make reimbursement evidence a competitive variable for molecular laboratories. Noridian’s 2025 MolDX revision and the FDA’s 2026 myeloma draft guidance show that payers and regulators evaluate clinical indications separately. Companies with established specimen logistics and physician ordering interfaces can compete through reliable turnaround and follow-up integration. Smaller assay developers may differentiate through disease-specific sensitivity or workflow simplicity, while broad-platform companies can spread manufacturing and service costs across many diagnostic areas.
October 2026: Pillar Biosciences launched the oncoReveal Myeloid v2 research panel with 80 genes, adding 22 targets to its earlier 58-gene design. The update emphasized improved handling of long and multiple FLT3 internal tandem duplications. The launch expands myeloid research capability but does not establish routine clinical diagnostic authorization. Source
September 2026: Adaptive Biotechnologies reported updates to NCCN myeloma guidance that describe highly sensitive MRD testing and identify clonoSEQ as an FDA-cleared assay. The change supports standardized assessment across treatment stages, although clinicians must follow the approved specimen and disease indications. Laboratories also need consistent sample handling and assay quality controls before reporting a negative MRD result. Source
May 2026: Illumina and SPT Labtech introduced the fireflyGO automation platform for targeted oncology sequencing workflows, including panels applicable to hematologic malignancies. Automated library preparation reduces manual steps and may help smaller laboratories adopt genomic research, subject to appropriate clinical validation for patient testing. The company positioned the workflow alongside Pillar’s targeted research panels rather than claiming blanket clinical clearance. Source
January 2026: The FDA issued draft guidance on using MRD negativity and complete response as endpoints in multiple myeloma accelerated-approval trials. The document discussed flow cytometry and sequencing-based assessment in marrow specimens, potentially increasing demand for rigorously validated monitoring assays in drug development. The guidance is draft and is not a standalone authorization for a new clinical diagnostic indication. Source
July 2025: Adaptive Biotechnologies and Flatiron Health integrated clonoSEQ ordering and results into OncoEMR for a network exceeding 4,500 clinicians. Electronic access can reduce administrative barriers to MRD follow-up in community oncology while preserving laboratory responsibilities for specimen acceptance and interpretation. The network includes community cancer sites that previously required more manual order and report exchanges. Source
June 2025: QIAGEN and Incyte announced development of a multimodal NGS companion panel focused initially on mutant CALR in myeloproliferative neoplasms. The project links targeted therapeutic development with genomic eligibility testing and plans regulatory submissions across the United States, Europe and Asia-Pacific. The partnership concerns an investigational treatment program, so commercial diagnostic authorization remains a future milestone. Source
The hematology oncology diagnostics market is forecast to increase from USD 3.1 billion in 2026 to USD 5.5 billion in 2034, a 7.4% CAGR. Growth depends on broader adoption of disease-specific genomic panels, repeat MRD testing and diagnostic access in countries expanding cancer services.
| Forecast variable | 2026 starting point | Expected 2034 effect |
|---|---|---|
| MRD testing | Guidance and reimbursement differ by disease | Repeat monitoring supports assay utilization |
| Molecular panel adoption | Specialist laboratories deploy NGS and dPCR | Higher test complexity raises per-case value |
| Laboratory automation | Manual library preparation remains common | Improved throughput can lower processing cost |
| Regional access | Reference networks concentrated in richer systems | Broader referrals expand eligible testing population |
In the United States, clinical adoption will depend on whether new molecular tests achieve recognized indications and reimbursement beyond established myeloma and selected lymphoma uses. The FDA’s January 2026 MRD draft guidance addresses trial endpoints rather than universal clinical coverage, while Noridian’s 2025 coding revision illustrates how narrow payer decisions can influence repeat testing. Laboratories offering clonoSEQ and other validated assays may benefit from improved physician ordering interfaces. More frequent monitoring can increase revenue without an equivalent rise in new leukemia diagnoses, but each additional test must be clinically justified.
European expansion will be tied to national commissioning and compliance with the in-vitro diagnostic regulation. NHS England’s seven genomic hubs demonstrate a scalable service model that centralizes sequencing expertise while allowing hospitals to initiate orders. Manufacturers must document performance and intended use under applicable rules, which may favor suppliers with established quality systems. Foresight’s multicenter lymphoma work in the Netherlands and Belgium illustrates how prospective evidence can support eventual clinical translation, although research findings are not the same as reimbursement approval.
Asia-Pacific has several pathways to higher testing intensity. Japan’s updated companion-diagnostic lists provide a defined authorization framework, Australia’s 2025 precision medicine investment supports complex genomic programs, and Chinese developers such as AmoyDx supply disease-specific panels. India’s laboratory networks can extend testing beyond tertiary centers when specimen logistics and prices are manageable. Price-sensitive markets may initially favor targeted PCR for known mutations, reserving broader sequencing for patients whose treatment decisions require more extensive characterization.
Latin America and Africa offer longer-term access opportunities rather than immediate parity with high-income markets. PAHO’s 2026 childhood cancer observatory and WHO’s 2026 survival dataset document diagnostic inequalities, while Brazil’s INCA shows that sophisticated hematologic molecular services are feasible at specialized public centers. Investments in training, pathology quality assurance and specimen transport must accompany equipment purchases. By 2034, companies able to supply validated assays with practical service support should be better positioned than vendors offering sequencing hardware without local interpretation capacity.
Coverage includes hematologic cancer diagnostic products and attributable clinical testing services across five regions for 2025, 2026 and 2034.
Global hematology oncology diagnostics revenue was estimated at USD 2.9 billion in 2025. The boundary includes blood-cancer-specific assays, dedicated testing equipment and attributable laboratory services, while excluding routine nonmalignant hematology tests and unrelated solid-tumor procedures. Spending varies by disease and the complexity of molecular characterization.
The market is projected to grow at 7.4% annually between 2026 and 2034. A USD 3.1 billion estimate for 2026 and USD 5.5 billion forecast for 2034 form the published model. Expansion reflects genomic profiling, repeat residual-disease monitoring and improved access to specialist laboratories.
Next-generation sequencing represented an estimated ~35% of 2025 technology revenue. Disease-focused panels can identify mutations, rearrangements and other clinically relevant variants in leukemia and lymphoma. Flow cytometry, targeted PCR, immunohistochemistry and cytogenetics remain necessary for complementary diagnostic questions.
Measurable residual disease testing detects small populations of malignant cells after treatment and helps evaluate response depth. The FDA issued January 2026 draft guidance on MRD negativity as a potential accelerated-approval trial endpoint in myeloma. Clinical ordering must follow the assay’s validated disease and specimen indications, and investigational tests remain subject to the trial protocol.
Leukemia is the leading modeled indication, representing an estimated ~42% of 2025 revenue. Acute and chronic leukemias require mutation classification and monitoring, while lymphoma and myeloma generate substantial immunophenotyping and MRD demand. Diagnostic intensity depends on therapy, risk group and the availability of specialized laboratories.
No. Adaptive Biotechnologies describes FDA-cleared clonoSEQ indications in multiple myeloma, B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia under specified specimens. Some lymphoma applications are offered as laboratory-developed tests, and Medicare coverage is indication-specific. Clinicians should confirm current labeling and payer policies before ordering.
Flow cytometry characterizes cellular immunophenotypes, whereas sequencing identifies DNA or RNA changes such as mutations and fusions. Both methods can support residual-disease assessment in defined settings, but their sensitivity and interpretation differ. The European LeukemiaNet 2025 update discusses disease-specific MRD approaches rather than a universal replacement test.
North America represented an estimated ~42% of global 2025 revenue. U.S. molecular reference laboratories, oncology specialists and reimbursement for selected monitoring indications support spending. Europe has established public genomic networks, while Asia-Pacific demand grows through domestic assay supply and precision-medicine investment.
Not automatically. Pillar oncoReveal Myeloid v2 and Thermo Fisher Oncomine Myeloid MRD are described by their suppliers as research-use products. Clinical testing requires an authorized or otherwise legally permitted intended use and appropriate laboratory validation. A high gene count does not by itself demonstrate clinical diagnostic suitability.
Roche, QIAGEN, Thermo Fisher Scientific, Illumina, Bio-Rad, Adaptive Biotechnologies, Invivoscribe, Amoy Diagnostics, Foresight Diagnostics and Pillar Biosciences participate through different assay and service categories. Roche emphasizes hematopathology reagents, while specialist companies focus on disease-specific molecular and MRD workflows.
Major constraints include instrument investment, sequencing consumable costs, trained personnel, specimen transport and evidence required for reimbursement. European IVDR rules and disease-specific U.S. coverage policies also affect commercialization. Reference laboratory networks can spread fixed costs, but underserved hospitals may still lack timely access to advanced testing.
The forecast reaches USD 5.5 billion in 2034 as molecular testing becomes more integrated with treatment selection and response monitoring. Public genomic commissioning, automated preparation and better cancer referral systems may increase volumes. Growth remains contingent on clinical validation, reimbursement and adequate laboratory staffing.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.